Biotechnology aiming to extend human life — sometimes framed as the search for immortality — is drawing rising sums and headlines, yet the science underpinning many claims remains provisional.
What is longevity biotechnology?
Longevity biotechnology is a subfield of biotech that seeks to address the biological processes that underlie ageing, with the aim of increasing healthspan (years lived in good health) and, in some cases, lifespan (total years lived). Unlike traditional drug discovery, which often designs chemicals to affect a target, longevity approaches may use biological systems or engineered cells to intervene in ageing-related mechanisms.
The idea of treating ageing itself is ancient. Contemporary efforts are fuelled by advances in genetic engineering, regenerative medicine and artificial intelligence. The result is a fast-growing industry and a flurry of research, investment and public expectation.
Promises, hype and hard evidence
High-profile interest from political leaders and large-scale funding has amplified attention. The reporting notes that Russia has reportedly directed billions of dollars towards organ transplantation research and regenerative medicine. Meanwhile, discussions among global leaders have highlighted ambitious predictions, including claims that humans might live to 150 years this century.
However, the scientific community emphasises caution. Early-stage findings can be intriguing — for example, identifying molecular pathways linked to ageing — but they do not amount to proven, safe interventions that extend healthy human life. The field mixes well-established biotechnologies (such as certain cell therapies) with experimental ideas that require far more clinical validation.
"The aim is simple: to treat the underlying biological mechanisms of age-related diseases"
That aim, while straightforward to state, faces complex biological realities. Ageing is not a single process; it is a collection of interacting mechanisms, including DNA damage, cellular senescence, metabolic change and immune decline. Intervening successfully in one pathway does not guarantee broad improvements in health or longevity.
- Health claims need rigorous trials: interventions must be tested in well-designed human studies to demonstrate safety and meaningful benefit.
- Translation is slow: findings in model organisms do not automatically translate to humans.
- Ethical and social implications: access, equity and the societal impacts of longer lives require policy attention.
Terms to know
| Term | Meaning |
|---|---|
| Longevity biotechnology | Biotechnological approaches aimed at treating mechanisms of ageing to increase healthspan or lifespan. |
| Healthspan | The period of life spent in good health, free from disabling disease. |
| Lifespan | The total length of time an individual is alive. |
For South Africa and other countries, the rise of longevity biotech raises practical questions: how should regulators assess experimental ageing therapies, how will public healthcare systems weigh early costly interventions, and what protections are needed to prevent misleading claims that exploit patients?
Policy makers must balance encouraging innovation with safeguarding public health. This includes ensuring that clinical trials are robust, that regulatory pathways require meaningful evidence of benefit, and that public funds and private investments are directed with realistic expectations.
Finally, public communication matters. The allure of extended life taps deep cultural and personal hopes, which can intensify demand for unproven remedies. Clear explanation of what current science can and cannot deliver will help citizens make informed decisions and will guide sound policy on investment, regulation and equitable access.
